Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy.

Advances in therapy - 1 Mar 2024

Mankan Arun K, Mankan Nagender, de Las Heras Begona, Ramkissoon Shakti H, Bodriagova Olga, Vidal Laura, Grande Enrique, Saini Kamal S

Abstract excerpt

Immune checkpoint inhibitors (ICI) have emerged as an important therapeutic approach for patients with cancers including bladder cancer (BC). This commentary describes a recent study that demonstrated that the loss of Y chromosome (LOY) and/or loss of specific genes on Y chromosome confers an aggressive phenotype to BC because of T cell dysfunction resulting in CD8+T cell exhaustion. Loss of expression of Y...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomes, Human, Y
Share to Histone Demethylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Minor Histocompatibility Antigens

Share to Phenotype

Share to Prognosis

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 38198042
DOI: 10.1007/s12325-023-02758-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy.PMID 38198042Read ↗

Y-Linked Lysine(K) Demethylase 5D as a regulator of sex-specific bladder cancer metastasis and prognosisSemantic proximity Read ↗

Y chromosome loss is a frequent early event in urothelial bladder cancerSemantic proximity Read ↗

<i>CEBPD</i>amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosisSemantic proximity Read ↗

E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapiesSemantic proximity Read ↗

Immune Checkpoint Inhibitor Resistance in Genitourinary Cancers: Mechanisms, Biomarkers, and Emerging Therapeutic StrategiesSemantic proximity Read ↗

Latest progress in molecular biology and treatment in genitourinary tumours.Semantic proximity Read ↗

The Central Role of Immune Checkpoint Receptors in Genitourinary Tumor Immunotherapy: Mechanisms, Biomarkers, and Therapeutic LandscapeSemantic proximity Read ↗

Loss of chromosome Y in primary tumorsSemantic proximity Read ↗

Loss of the Y chromosome in bladder cancer drives metabolic reprogrammingSemantic proximity Read ↗

The Y chromosome gene KDM5D restrains CD8+ T cell antitumor immunity through TCR and cholesterol-exhaustion programsSemantic proximity Read ↗

Polymorphisms in immune checkpoint genes might influence bladder cancer risk and clinical outcome.Semantic proximity Read ↗

EZH2 in Bladder Cancer, a Promising Therapeutic TargetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.